Phase I/II Study of the Combination of BKM120 and Bevacizumab in Patients With Refractory Solid Tumors (Phase I) and Relapsed/Refractory Glioblastoma Multiforme (Phase II)
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 02 Feb 2018
At a glance
- Drugs Bevacizumab (Primary) ; Buparlisib (Primary)
- Indications Glioblastoma; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors SCRI Development Innovations
- 03 Oct 2017 Planned End Date changed from 1 Aug 2017 to 1 Feb 2018.
- 16 Jan 2017 Planned End Date changed from 1 Jun 2017 to 1 Aug 2017.
- 28 Jul 2016 Planned End Date changed from 1 Dec 2016 to 1 Jun 2017.